Physician profile

Paul J Kinde

Family Medicine · La Joya, TX

NPI 1396768594

$4,102.95

in general payments reported to CMS, 2019-2025

40 companies · $672 in 2025

The $672 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).

See the full distribution for Family Medicine

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,368.37
Education$19.62

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $570.79 2020-2025
Lilly USA, LLC $464.30 2021-2025 Mounjaro, Zepbound, Jardiance
Amgen INC. $364.98 2022-2025 Otezla, Repatha, Repatha
Astrazeneca Pharmaceuticals LP $284.91 2019-2025 Farxiga, Airsupra
Otsuka America Pharmaceutical, INC. $258.20 2023-2025 Rexulti, Abilify Maintena
Novartis Pharmaceuticals Corporation $248.83 2021-2025
Ironwood Pharmaceuticals, INC $188.88 2019-2024 Linzess
Novo Nordisk INC $160.45 2019-2025 Ozempic, Rybelsus, Wegovy
Pfizer INC. $156.06 2021-2024
Janssen Pharmaceuticals, INC $134.62 2021-2023 Xarelto
Eisai INC. $121.59 2020-2025
Glaxosmithkline, LLC. $112.96 2021-2023 Trelegy Ellipta
Amarin Pharma, INC. $102.94 2019-2021
Exact Sciences Corporation $98.87 2024-2025 Cologuard Collection Kit
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $93.82 2019-2025 Xifaxan, Trulance
Show all 40 companies
CompanyGeneral paymentsYearsTop products
Bayer Healthcare Pharmaceuticals INC. $67.48 2023
Dexcom, INC. $66.97 2021-2024 Dexcom G6 Transmitter
Abbott Laboratories $59.01 2021-2024 Freestyle Libre 3
Redhill Biopharma INC. $51.93 2021-2022
Kowa Pharmaceuticals America, INC. $45.19 2022
Astellas Pharma US INC $42.91 2019-2021
Esperion Therapeutics, INC. $42.84 2021-2024 Nexletol
Biohaven Pharmaceutical Holding Company LTD. $37.35 2022
Allergan, INC. $34.84 2020
Genentech USA, INC. $30.25 2021-2022
Sumitomo Pharma America, INC. $25.56 2024 Gemtesa
Biotronik Nro, INC. $21.54 2025 Prospera
Ani Pharmaceuticals, INC. $20.68 2025 Purified Cortrophin Gel
Optinose US, INC. $20.31 2023
Alk-Abello, INC $19.27 2025 Odactra, Ragwitek, Grastek
Paratek Pharmaceuticals, INC. $19.14 2023 Nuzyra
Merck Sharp & Dohme LLC $16.75 2021
Biohaven Pharmaceuticals, INC. $16.43 2021
Mylan Specialty L.P. $16.27 2021
Shield Therapeutics INC $16.03 2024
Mannkind Corporation $15.07 2021
Axsome Therapeutics, INC. $14.23 2025 Auvelity
Alexion Pharmaceuticals, INC. $14.17 2023
Cipher Pharmaceuticals US LLC $13.74 2025 Spinosad, Natroba
Si-Bone, INC. $12.79 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Paul J Kinde

$4,102.95

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbvie INC.
Context
The $672 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/858162/paul-j-kinde

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.